In this issue of Clinical Watch, we highlight the NIH Panel recommendations regarding medications associated with COVID-19 treatment and suggest prior authorization criteria for the first approved treatment for erythropoietic protoporphyria. Lastly, we review claims data to identify potential users for a new treatment for heavy menstrual bleeding associated with uterine fibroids.
For more information about a specific topic, please contact Janelle Sheen or Karen Powell. Be sure to stay tuned for future monthly updates. For more information about our solutions, please visit conduent.com/pharmacysolutions.